Vitamin D acts directly on the gene that encodes LL-37, not through some indirect immune effect. The CAMP gene on human chromosome 3p21.3 carries a vitamin D response element in its proximal promoter, and the active metabolite switches transcription on through the vitamin D receptor. The molecular account is well characterized in human cells; what supplementation does to LL-37 in people is a separate and far less settled question.
Vitamin D drives LL-37 production by binding the vitamin D receptor to a response element in the CAMP promoter, a direct genomic effect established in human cells by Wang and colleagues and Gombart and colleagues in 2004 and 2005.
The distinction that matters here is which metabolite does the work. Only 1,25-dihydroxyvitamin D3, the double-hydroxylated form, binds the vitamin D receptor with high enough affinity to move the gene; cholecalciferol in a capsule and the 25-hydroxyvitamin D reported on a lab panel do not. Everything downstream is a standard nuclear receptor circuit with one antimicrobial gene at the end of it.
Gombart and colleagues mapped a consensus vitamin D response element in the CAMP promoter in 2005 and showed direct vitamin D receptor binding to it, the evidence that the effect is genomic rather than secondary, with CYP24A1 induced alongside CAMP to catabolize calcitriol and close the loop.
The answer is a transposable element, not a conserved piece of ancient biology. The response element sits inside an AluSx short interspersed nuclear element that inserted upstream of CAMP in the primate lineage and carried a sequence close enough to canonical that a few point mutations turned it into a working switch. Alu elements are primate-specific, so rodents do not have a weaker version of this pathway; they have no version of it.
| Criteria | Human CAMP | Mouse Camp |
|---|---|---|
| Vitamin D response element | Present, inside an AluSx element | Absent entirely |
| Calcitriol induction | Several-fold to more than tenfold | Not induced |
| Peptide product | LL-37, 37 residues | CRAMP |
| Main transcriptional drivers | Vitamin D receptor, C/EBP factors | C/EBP factors, myeloid differentiation |
The vitamin D response element in the human CAMP promoter sits inside a primate-specific AluSx element that rodent promoters lack, described as an exaptation by Gombart, Borregaard, and Koeffler in 2005, which means a mouse study of vitamin D and innate immunity is testing an animal in which the central human mechanism does not exist.
Most accounts of vitamin D stop at the kidney, and that is exactly where the cathelicidin story parts from the calcium story. Monocytes, macrophages, dendritic cells, keratinocytes, and airway and intestinal epithelium all carry CYP27B1, generate the active hormone inside themselves, and act on their own genome, an arrangement described as intracrine rather than endocrine. The detail carries weight for anyone reading an infection study, because it is why vitamin D status, not the calcitriol level on a blood panel, is the variable that keeps reappearing.
Liu and colleagues reported in 2006 that human monocytes cultured in serum from vitamin D deficient donors failed to induce cathelicidin after TLR2/1 stimulation, and that adding 25-hydroxyvitamin D back to that serum restored the response.
An infection signal has to supply both halves of the circuit at once, and TLR2/1 is the trigger that defined this field. Engagement of that receptor pair raises the vitamin D receptor and CYP27B1 in the same cell, converting a resting macrophage into one that can take up circulating 25-hydroxyvitamin D, activate it in place, and induce its own cathelicidin. Without the receptor there is nothing for the hormone to act on, and without the hydroxylase there is no hormone.
TLR2/1 engagement supplies both halves of the circuit in one move, raising the vitamin D receptor and CYP27B1 in the same macrophage, the 2006 Science finding by Liu and colleagues that made tuberculosis the proving ground for the pathway and linked cathelicidin to autophagy in infected macrophages.
The human data are weaker and messier than the mechanism would predict. Supplementation reliably raises serum 25-hydroxyvitamin D in a dose-dependent way; what it does to LL-37 is inconsistent across randomized trials, with some reporting increases in circulating or tissue cathelicidin and several finding no measurable change. The positive results are not scattered at random, and where they cluster is the most useful part of the record.
Vitamin D is necessary for the cathelicidin pathway to run, but supplementing beyond sufficiency is not an established way to raise LL-37 or to gain clinical benefit, and the trials capable of answering the question cleanly, enrolling deficient participants and sampling the relevant tissue during an actual immune challenge, have mostly not been done.
What gives this question weight is that the other inputs to CAMP do not depend on vitamin D status at all. Butyrate and other short-chain fatty acids, produced by colonic microbial fermentation of dietary fiber, induce cathelicidin strongly in colonic epithelium by a separate route: histone deacetylase inhibition that opens the chromatin at the promoter, plus MEK/ERK signaling. Because one input supplies a ligand-activated transcription factor and the other makes the locus accessible, the two combine more than additively.
Because butyrate and vitamin D reach the CAMP promoter by different mechanisms, the promoter can in principle be driven without vitamin D at all through HDAC inhibitors or butyrate delivery, an approach described as host-directed therapy that reported enhanced cathelicidin expression in small pulmonary tuberculosis trials but remains investigational rather than established care.
Skin has the strongest claim, and the logic loops back on itself neatly: keratinocytes make cholecalciferol from 7-dehydrocholesterol under UVB, carry both CYP27B1 and the vitamin D receptor, and then respond to the hormone they built. The pattern across the body is that the vitamin D route matters most at barrier surfaces that have to induce the peptide against a local challenge, and least where the peptide is pre-made and stored.
The vitamin D route governs cathelicidin where a barrier surface must induce the peptide on demand, chiefly skin and airway, while the largest LL-37 reservoir in the body is pre-loaded into neutrophil granules during granulopoiesis, which is why plasma LL-37 tracks neutrophil biology more closely than vitamin D status.
Elevated cathelicidin is a real feature of several inflammatory conditions, and the established observations need separating from the tempting inference. That inference, that raising vitamin D would worsen these diseases by raising LL-37, does not survive contact with the clinic: topical vitamin D analogs such as calcipotriol are a mainstay of psoriasis treatment and improve the disease. Vitamin D signaling in skin promotes keratinocyte differentiation, restrains proliferation, and shifts T-cell responses toward a regulatory phenotype, and those effects outweigh whatever cathelicidin induction contributes.
There is no good evidence that oral vitamin D supplementation aggravates psoriasis or rosacea, since the pathway is substrate-limited and self-braked by CYP24A1, and the real ceiling on intake is calcium toxicity rather than LL-37, with the adult tolerable upper intake level set at 4000 IU per day and granulomatous disease such as sarcoidosis requiring medical supervision before any supplementation.
Educational use only. This article describes what the published scientific and clinical literature reports about LL-37. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
